Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for post-exposure prophylaxis: A phase 2/3 randomized, single blind, non-inferiority, controlled study

Clinical Infectious Diseases Oct 04, 2017

Gogtay NJ, et al. - Researchers here investigated a recombinant human monoclonal antibody (SII RMAb) in a post-exposure prophylaxis (PEP) regimen in comparison to a human rabies immunoglobulin (HRIG)-containing PEP regimen. In this study, a PEP regimen containing SII RMAb proved safe and was non-inferior to HRIG PEP in RVNA production. They observed the novel monoclonal to be a safe and potent alternative for the passive component of PEP. It seemed to have potential for significantly improving the management of bites from suspected rabid animals.
Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen